– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed – – In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity ...
– Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation – “We are pleased to highlight ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today ...
SOUTH SAN FRANCISCO, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address ...
Please provide your email address to receive an email when new articles are posted on . LONDON — Therapy combining small interfering RNA, capsid assembly modulator and nucleotide analogue reduced ...
Aligos Belgium presented research on ALG-005398, a first representative of a series of non-heteroaryldihydropyrimidines (HAPs) class I capsid-assembly modulators, that was identified using ...
Current therapies for chronic hepatitis B virus (HBV) infection can effectively suppress viral replication but do not achieve a functional or complete cure. Capsid assembly modulators inhibit the ...
– Phase 1b study will evaluate safety, pharmacokinetic and efficacy endpoints in participants with chronic hepatitis B virus infection with interim data expected by the end of 2024 – SOUTH SAN ...
– Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation – SOUTH SAN FRANCISCO, Calif., Nov ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results